ASCEnD is an open label, 1:1 randomised, controlled, pragmatic trial which compares the clinical and cost-effectiveness of an aripriprazole/sertraline combination with quetiapine in the treatment of bipolar depression.
The study is being led by Dr Stuart Watson of Newcastle University and Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust. You can find out more about the rest of the team here: Our Team
You can find which sites around the UK are recruiting to the study here: Sites
Funding
The trial is funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme - Call 19/130 Bipolar Disorder. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Sponsorship
The Study is sponsored by Cumbria, Northumberland, Tyne & Wear NHS Foundation Trust.
Management
The trial is managed by Newcastle Clinical Trials Unit (NCTU) - UKCRC Registered Clinical Trials Unit.
